The Boards of Directors for AllianceBernstein Global High Income Fund and AllianceBernstein National Municipal Income Fund have selected PricewaterhouseCoopers LLP as their independent registered public accounting firm. This decision, made during meetings held in early November 2026, covers the fiscal years ending March 31, 2027, and October 31, 2027, respectively. The appointment ensures continued independent financial oversight for these closed-end investment funds managed by AllianceBernstein. Investors can expect audited financial statements for these periods from PwC.
AllianceBernstein Global High Income Fund and National Municipal Income Fund auditor change provides context for readers. For readers following Financials, here is Pluang's market snapshot as of Nov 12, 2026 04:12 WIB: 94 of 142 US Financial stocks rose, 47 fell. Notable movers include BMNR at USD 19.27 (+6.58%), IBKR at USD 82.57 (+6.42%), and CLSK at USD 6.92 (+5.33%).
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
